Drugs / RODUCITABINE
RODUCITABINE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03189914 | Oct 2017 → Oct 2019 | malignant pancreatic neoplasm | Processa Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT02030067 | Dec 2013 → Jul 2019 | urinary bladder cancer | Processa Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-08-07 | Ocuphire Pharma, Inc. | Results Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development opusgtx.com ↗
As of July 24, 2019, an overall response rate of 23% has been observed in 40 patients that have had at least one scan on treatment in the Phase 2a study of RX-3117 in combination with ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) in patients newly diagnosed with metastatic pancreatic cancer. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-06-17 | Processa Pharmaceuticals | PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117 processapharmaceuticals.com ↗ |
| 2019-08-07 | Ocuphire Pharma, Inc. | Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development opusgtx.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RODUCITABINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2064455 ↗ |
| Known as | Fluorocyclopentenylcytosine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2064455 ↗ |
| Known as | RX-3117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02030067 ↗ |
| Known as | TV-1360 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2064455 ↗ |
| Modality | Small molecule | — CHEMBL2064455 ↗ |
| Route | Oral | “RX-3117 Administered Orally as a Single-Agent” NCT02030067 ↗ |